Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition
Year: 2018
Type: article
Abstract: Mutations in BRAF outside of the 600 codons (BRAF non- V600) occur across cancer types, including in 3% to 5% of melanomas. The optimal treatment strategies are not clear but based on preclinical studies could include MEK inhibitors. Combining BRAF and MEK inhibitors in this population may provide additional benefit. See related article by Dankner et al., p. 6483
Source: Clinical Cancer Research
Authors: Douglas B. Johnson, Kimberly B. Dahlman
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: G1002678292, G2593326646, Predicting and profiling long-term survival after immune checkpoint inhibition, Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension, G8749095108, Vanderbilt Clinical Oncology Research Career Development Award, Cancer Center Support Grant, Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
OpenAlex ID: W2883573751